{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Christine Lam"}, {"accession": "MS:1000589", "name": "contact email", "value": "christine.yt.lam@ucsf.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "UCSF"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Arun Paul Wiita"}, {"accession": "MS:1000589", "name": "contact email", "value": "Arun.Wiita@ucsf.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Laboratory Medicine, Wiita Lab, University of California San Francisco"}]}], "datasetFiles": [{"accession": "PRIDE:0000408", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/txt.zip"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20161111-10.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20161111-12.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20161111-14.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20161123-11.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20170309-06 DMSO cocult.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20170309-08 1.5 hr.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20170309-10 24 hr.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581/Q20170309-12 mono.raw"}], "description": "The myeloma bone marrow microenvironment drives proliferation of malignant plasma cells and promotes resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought to be central components of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow mesenchymal stromal cells.Here, we validated both in vitro, in stromal-responsive human myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in myeloma models.  Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects.  Combination with a novel irreversible JAK3-selective inhibitor also did not rescue ruxolitinib effects. RNA-seq and unbiased phosphoproteomics revealed that marrow stromal cells drive a JAK/STAT-mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large majority of these pro-growth signals. Taken together, our results suggest that tofacitinib specifically reverses the growth-promoting effects of the tumor microenvironment through blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results can be rapidly translated into potential clinical benefits for myeloma patients.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD006581"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD006581"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD006581"}], "instruments": [{"accession": "MS:1002634", "name": "Q Exactive Plus"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "human, myeloma, tofacitinib, bone marrow microenvironment,  LC-MSMS, LFQ"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "29622655"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 103(7):1218-1228"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment"}